Hikal Ltd
Shivani Bhasin Sachdeva is the Founder & CEO of India Alternatives, a reputable mid-market private equity fund focused on investing behind transformational themes in India. She has over 18 years of global private equity experience in the US and in India at top private equity funds, including GE Equity, Lightyear Capital and IDFC Private Equity. Shivani has been an active member on the boards of all her portfolio companies, where she has been instrumental in guiding management teams and shaping strategy. Shivani has previously served on the boards of HealthCare Global and Gokaldas Intimatewear, and currently serves on the boards of Brinton Pharmaceuticals and Seclore Technology. She is also an Independent Director at Emaar India. Shivani has received several accolades and recognition for being one of the top women leaders in finance in India, including winning an award for the Top 25 Women Leaders in Finance category by Association of International Wealth Management of India as part of India's Top 100 Women in Finance campaign. She is a frequent speaker on private equity at domestic and international conferences, including Super Return Europe and Singapore and the Indian Venture Capital Association. Shivani received an MBA from the Wharton School, University of Pennsylvania, and a B.A. in Economics from Mount Holyoke College (Phi-Beta-Kappa, Magna Cum Laude, Sarah Williston Scholar).
This person is not in the org chart
This person is not in any offices
Hikal Ltd
1 followers
Hikal Limited is engaged in the manufacturing of various chemical intermediates, specialty chemicals, active pharmaceutical ingredients (APIs) and contract research activities. The Company offers pharmaceuticals and agrochemicals. Its segments include Crop Protection and Pharmaceuticals. It offers agrochemicals, including active ingredients, such as Ammonium dithiocarbamate, Amitrole Tech, Diuron Tech, Ethion Tech, Imazalil Tech, Isoproturon Tech, Meta chloro Aniline (MCA), Quinalphos Tech and Temephos Tech, and intermediates and specialty chemicals, such as Phenyl-2-(phenylthio)-phenyl carbamate, 4-(Benzyloxy) Aniline Hydrochloride, N-Benzylpiperidine-4-carboxaldehyde, 3-Chloroaniline and 4 Aminobenzylamine. Its APIs include Gabapentin, Pregabalin, Levetiracetam, Quetiapine Fumarate, Memantine Hydrochloride, Venlafaxine Hydrochloride and Donepezil Hydrochloride. The Company operates in geographical areas, including India, Europe, the United States, Canada and South East Asia.